Interactions between hepatitis B virus and aflatoxin B 1: Effects on p53 induction in hepaRG cells

Journal of General Virology

Volumn 93, Issue 3, 2012, Pages 640-650

  Lereau, Myriam ^a,b   Gouas, Doriane ^b   Villar, Stéphanie ^b   Besaratinia, Ahmad ^c   Hautefeuille, Agnés ^b   Berthillon, Pascale ^a   Martel Planche, Ghislaine ^b   da Costa, André Nogueira ^b   Ortiz Cuaran, Sandra ^b   Hantz, Olivier ^a   Pfeifer, Gerd P ^c   Hainaut, Pierre ^b,d   Chemin, Isabelle ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PROTEIN P53; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL LINE; CHRONIC LIVER DISEASE; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENZYME INDUCTION; HEPARG CELL; HEPATITIS B VIRUS; LIVER CELL CARCINOMA; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VIRUS REPLICATION;

AFLATOXIN B1; CELL LINE; DNA DAMAGE; HEPATITIS B VIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84857066990     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.032482-0     Document Type: Article

References (37)

1. Aguilar, F., Hussain, S. P. & Cerutti, P. (1993). Aflatoxin B1 induces the transversion of GAT in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 90, 8586-8590.
2. Andrieux, L. O., Fautrel, A., Bessard, A., Guillouzo, A., Baffet, G. & Langouët, S. (2007). GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 67, 2114-2123.
3. Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouët, S., Morel, F., Guguen-Guillouzo, C. & Guillouzo, A. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34, 75-83.
4. Barraud, L., Guerret, S., Chevallier, M., Borel, C., Jamard, C., Trepo, C., Wild, C. P. & Cova, L. (1999). Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Hepatology 29, 1317-1323.
5. Barraud, L., Douki, T., Guerret, S., Chevallier, M., Jamard, C., Trepo, C., Wild, C. P., Cadet, J. & Cova, L. (2001). The role of duck hepatitis B virus and aflatoxin B1 in the induction of oxidative stress in the liver. Cancer Detect Prev 25, 192-201.
6. Besaratinia, A., Kim, S. I., Hainaut, P. & Pfeifer, G. P. (2009). In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 137, 1127-1137, 1137.e5.
7. Bosch, F. X., Ribes, J. & Borràs, J. (1999). Epidemiology of primary liver cancer. Semin Liver Dis 19, 271-285.
8. Bressac, B., Kew, M., Wands, J. & Ozturk, M. (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429-431.
9. Chemin, I., Ohgaki, H., Chisari, F. V. & Wild, C. P. (1999). Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver 19, 81-87.
10. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C. & Parkin, D. M. (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]: Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr
11. Ganem, D. & Prince, A. M. (2004). Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350, 1118-1129.
12. Gouas, D., Shi, H. & Hainaut, P. (2009). The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 286, 29-37.
13. Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C. & Guguen-Guillouzo, C. (2002). Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99, 15655-15660.
14. Hantz, O., Parent, R., Durantel, D., Gripon, P., Guguen-Guillouzo, C. & Zoulim, F. (2009). Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 90, 127-135.
15. Hollstein, M. & Hainaut, P. (2010). Massively regulated genes: the example of TP53. J Pathol 220, 164-173.
16. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J. & Harris, C. C. (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-428.
17. Jennen, D. G., Magkoufopoulou, C., Ketelslegers, H. B., van Herwijnen, M. H., Kleinjans, J. C. & van Delft, J. H. (2010). Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115, 66-79.
18. Jia, L., Wang, X. W. & Harris, C. C. (1999). Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 80, 875-879.
19. Kew, M. C. (2003). Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23, 405-409.
20. Le Guillou, D. B., Duclos-Vallée, J. C., Eberle, F., Capel, F. & Petit, M. A. (2000). Evaluation of an enzyme-linked immunosorbent assay for detection and quantification of hepatitis B virus preS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA. J Viral Hepat 7, 387-392.
21. Lleonart, M. E., Kirk, G. D., Villar, S., Lesi, O. A., Dasgupta, A., Goedert, J. J., Mendy, M., Hollstein, M. C., Montesano, R. & other authors (2005). Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 14, 2956-2962.
22. Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M., Zoulim, F., Hantz, O. & Protzer, U. (2011). Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55, 996-1003.
23. Lunn, R. M., Zhang, Y. J., Wang, L. Y., Chen, C. J., Lee, P. H., Lee, C. S., Tsai, W. Y. & Santella, R. M. (1997). p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 57, 3471-3477.
24. McGlynn, K. A. & London, W. T. (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19, 3-23.
25. Ozturk, M. (1991). p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338, 1356-1359.
26. Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N. & Groopman, J. D. (1994). A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3, 3-10.
27. Ross, R. K., Yu, M. C., Henderson, B. E., Yuan, J.-M., Qian, G.-S., Tu, J.-T., Gao, Y.-T., Wogan, G. N. & Groopman, J. D.(1992). Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943-946.
28. Sarasin, A. R., Smith, C. A. & Hanawalt, P. C. (1977). Repair of DNA in human cells after treatment with activated aflatoxin B1. Cancer Res 37, 1786-1793.
29. Sells, M. A., Chen, M. L. & Acs, G. (1987). Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84, 1005-1009.
30. Smela, M. E., Hamm, M. L., Henderson, P. T., Harris, C. M., Harris, T. M. & Essigmann, J. M. (2002). The aflatoxin B1 formamidopyr-imidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 99, 6655-6660.
31. Sylla, A., Diallo, M. S., Castegnaro, J. & Wild, C. P. (1999). Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat Res 428, 187-196.
32. Untergasser, A., Zedler, U., Langenkamp, A., Hösel, M., Quasdorff, M., Esser, K., Dienes, H. P., Tappertzhofen, B., Kolanus, W. & Protzer, U. (2006). Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547.
33. Wang, L. Y., Hatch, M., Chen, C. J., Levin, B., You, S. L., Lu, S. N., Wu, M. H., Wu, W. P., Wang, L. W. & other authors (1996). Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 67, 620-625.
34. Waters, R., Jones, C. J., Martin, E. A., Yang, A. L. & Jones, N. J. (1992). The repair of large DNA adducts in mammalian cells. Mutat Res 273, 145-155.
35. WHO (2002). Evaluation of carcinogenic risks to humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene, vol. 82, pp. 301-366. Lyon, France: IARC Press.
36. Williams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M. & Aggarwal, D. (2004). Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80, 1106-1122.
37. Zhang, Y. J., Chen, C. J., Lee, C. S., Haghighi, B., Yang, G. Y., Wang, L. W., Feitelson, M. & Santella, R. (1991). Aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis 12, 2247-2252.